Choosing wisely in daily practice: a mixed methods study on determinants of antinuclear antibody testing by rheumatologists.
Scand. J. Rheumatol. 2016 Jul;():1-6
Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study.
Scand. J. Rheumatol. 2016 Jul;():1-4
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
PLoS ONE 2016 ;11(6):e0157961
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Arthritis Res. Ther. 2016 Jun;18():145
Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.
Ann. Rheum. Dis. 2016 Nov;75(11):1899-1901
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.
Arthritis Res. Ther. 2016 Jun;18(1):144
Systemic lupus erythematosus.
Nat Rev Dis Primers 2016 Jun;2():16039
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
Ann. Rheum. Dis. 2016 Aug;75(8):1428-37
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab.
RMD Open 2016 ;2(1):e000213
New therapeutic approaches in rheumatoid arthritis.
Presse Med 2016 Jun;45(6 Pt 2):e179-92
Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.
Ann. Rheum. Dis. 2016 May;():
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Ann. Rheum. Dis. 2016 May;():
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.
Ann. Rheum. Dis. 2016 Jul;75(7):1268-71
Infliximab versus Conventional Combination Treatment and 7-Year Work Loss in Early RA: Results of the Randomized Swefot Trial.
Arthritis Care Res (Hoboken) 2016 Mar;():
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis.
Ann. Rheum. Dis. 2016 Mar;():
Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
Lupus 2016 Jun;25(7):699-709
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Rheumatology (Oxford) 2016 Jun;55(6):1031-41
The association between diet and glucocorticoid treatment in patients with SLE.
Lupus Sci Med 2016 ;3(1):e000135
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
RMD Open 2016 ;2(1):e000133
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
Ann. Rheum. Dis. 2016 Nov;75(11):1939-1944
Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment.
Nat Rev Rheumatol 2016 Mar;12(3):135-6
Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
Ann. Rheum. Dis. 2016 Jul;75(7):1272-8
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.
Ann. Rheum. Dis. 2016 Jan;75(1):16-22
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.
Ann. Rheum. Dis. 2016 Jan;75(1):3-15
The frequency and outcome of lupus nephritis: results from an international inception cohort study.
Rheumatology (Oxford) 2016 Feb;55(2):252-62
Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
Ann. Rheum. Dis. 2016 Jan;75(1):52-8
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Rheumatology (Oxford) 2016 Feb;55(2):230-6
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Ann. Rheum. Dis. 2016 Feb;75(2):356-61
Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists.
Arthritis Care Res (Hoboken) 2016 Apr;68(4):562-9
Does disease activity at start of biologic therapy influence work-loss in RA patients?
Rheumatology (Oxford) 2016 Apr;55(4):729-34
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Ann. Rheum. Dis. 2016 Feb;75(2):332-40
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
Ann. Rheum. Dis. 2016 Jul;75(7):1336-42
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
Ann. Rheum. Dis. 2016 Jun;75(6):1081-91
Arthritis Care Res (Hoboken) 2016 Jul;68(7):1053-4
Arthritis Care Res (Hoboken) 2016 Jul;68(7):1051
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Arthritis Res. Ther. 2015 Nov;17():325
Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging.
RMD Open 2015 ;1(1):e000106
Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients.
Value Health 2015 Nov;18(7):A647-8
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
J. Rheumatol. 2015 Dec;42(12):2288-95
Remission in SLE: closing in on the target.
Ann. Rheum. Dis. 2015 Dec;74(12):2103-6
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.
RMD Open 2015 ;1(1):e000044
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Arthritis Res. Ther. 2015 Sep;17():245
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.
Ann. Rheum. Dis. 2015 Dec;74(12):2260-1
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.
J. Rheumatol. 2015 Oct;42(10):1761-6
Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
Arthritis Res. Ther. 2015 Aug;17():181
Does disease activity at the start of biologic therapy influence health care costs in patients with RA?
Rheumatology (Oxford) 2015 Aug;54(8):1472-7
Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Ann. Rheum. Dis. 2015 Aug;74(8):1509-14
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Ann. Rheum. Dis. 2015 May;74(5):890-6
Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
Ann. Rheum. Dis. 2015 Jun;74(6):1212-7
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.
Ann. Rheum. Dis. 2015 Aug;74(8):1530-6
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Ann. Rheum. Dis. 2015 Jun;74(6):1094-101
Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Scand. J. Rheumatol. 2015 ;44(6):431-7
Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
Scand. J. Rheumatol. 2015 ;44(5):348-53
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.
Ann. Rheum. Dis. 2015 Aug;74(8):1567-70
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
BMJ 2015 Apr;350():h1389
Treatment Algorithms in Systemic Lupus Erythematosus.
Arthritis Care Res (Hoboken) 2015 Sep;67(9):1237-45
The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Ann. Rheum. Dis. 2015 Jun;74(6):970-8
Anti-C1q antibodies in systemic lupus erythematosus.
Lupus 2015 Jan;24(1):42-9
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
Ann. Rheum. Dis. 2015 Jan;74(1):96-103
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Ann. Rheum. Dis. 2015 Jun;74(6):1102-9
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
Ann. Rheum. Dis. 2015 Sep;74(9):1706-13
Differences and similarities in rheumatology specialty training programmes across European countries.
Ann. Rheum. Dis. 2015 Jun;74(6):1183-7